JJ_Photo_Skyline of J&J building_JJ_1Star.JPG

Newsroom

The latest news, information, and stories from Johnson & Johnson Innovative Medicine EMEA.

Press releases

The content in this section is intended for journalists.

86 Results

Filters

86 Results

Selected

Clear All

Immunology

New post-hoc analysis pooling two clinical trials demonstrates endoscopic response as a predictor of positive long-term patient outcomes in Crohn’s disease, including clinical remission and improved quality of life

Pooled data for guselkumab and ustekinumab in moderate-to severe Crohn’s disease demonstrated a higher percentage of patients with endoscopic response at year 1 achieved long-term response and remission at year 2 vs patients with no endoscopic response.¹

October 10, 2024

Learn more
Immunology

TREMFYA® (guselkumab) demonstrates robust results across biologic-naïve and biologic-refractory patients in Crohn’s disease and ulcerative colitis

Guselkumab is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of people living with Crohn’s disease, inclusive of those who are biologic-naïve and biologic-refractory ¹

Ninety percent more biologic-naïve patients and three times more biologic-refractory patients living with ulcerative colitis achieved endoscopic remission with guselkumab compared to placebo ²

October 10, 2024

Learn more
Oncology

DARZALEX® (daratumumab) subcutaneous (SC) formulation-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned

Study demonstrates a minimal residual disease (MRD)-negativity rate of 60.9 percent and 43 percent reduction in the risk of progression or death ¹

Phase 3 CEPHEUS study results presented in late-breaking oral presentation at the International Myeloma Society (IMS) Annual Meeting ¹

September 27, 2024

Learn more
Oncology

CARVYKTI® ▼ (ciltacabtagene autoleucel; cilta-cel) is the first cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line

45 percent reduction in risk of death achieved with cilta-cel versus standard therapies after three-year follow-up in landmark CARTITUDE-4 study¹

Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting¹

September 27, 2024

Learn more
Oncology

Novel combination of TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) suggest high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease

Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to talquetamab and teclistamab monotherapies¹

September 27, 2024

Learn more
Oncology

TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma

Updated data show 100 percent overall response rate, with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific antibody¹

Safety profile, including infection rates, is similar to talquetamab and daratumumab SC monotherapies¹

September 27, 2024

Learn more
Oncology

DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma

Recommendation supported by findings from quadruplet therapy PERSEUS study with daratumumab subcutaneous (SC) formulation in the frontline setting

Findings showed 60 percent reduction in risk of disease progression or death with daratumumab SC quadruplet regimen compared to current standard of care triplet regimen¹

September 20, 2024

Learn more
Oncology

New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer

Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)- unresponsive¹

September 15, 2024

Learn more

CP-459038
September 2024

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

Press releases